Athena Athena

X
[{"orgOrder":0,"company":"KM Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's KM Biologics Begins Clinical Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by KM Biologics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The first volunteer was injected with the inactivated virus vaccine known as KD-414, the company said in a release. The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune response.

            Lead Product(s): KD-414

            Therapeutic Area: Infections and Infectious Diseases Product Name: KD-414

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY